Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Chenghe Acquisition III Posts Q3 2026 Net Income of $975,037

Chenghe Acquisition III Co. filed its Form 10-Q for the quarter ended September 30, 2026, with the SEC on November 12, 2026, reporting quarterly net income of $975,037 and total assets of $131,521,148.

Aditi Sarkar | 12 November 2026

Imunon Q3 2026: Cash Falls to $4.04M, Restricted Cash Rises

Imunon, Inc. filed its quarterly report on Form 10-Q with the SEC on November 12, 2026, covering the fiscal quarter ended September 30, 2026, disclosing condensed consolidated financial statements and management discussion for the period.

Manish Choudhary | 12 November 2026

Vivani Medical SLIM-1 Phase 1 Trial Shows No NPM-139 Treatment-Related Adverse Events

Vivani Medical, Inc. filed a Form 8-K on November 12, 2026, reporting top-line results from its SLIM-1 Phase 1 clinical trial of NPM-139, a semaglutide implant, alongside its third quarter 2026 financial results.

Nitish Kishor | 12 November 2026

Patriot National Bancorp Q3 2026: Net Income of $1.2M

Patriot National Bancorp, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 12, 2026, reporting a return to quarterly net income after a year-to-date loss.

Manish Choudhary | 12 November 2026

Kyverna Therapeutics Q3 2026: $41.9M Net Loss, $133M Equity

Kyverna Therapeutics, Inc. filed its quarterly report on Form 10-Q with the SEC on November 12, 2026, covering the three and nine months ended September 30, 2026, disclosing a net loss of $41.9 million for the quarter and total stockholders' equity of $133.2 million.

Vinay Lochav | 12 November 2026

Creatd Reports Q3 2026 Net Loss of $2.86M

Creatd, Inc. filed a Form 10-Q with the SEC on November 12, 2026, covering the quarterly period ended September 30, 2026, disclosing a net loss of $2,855,134 from continuing operations for the three months ended September 30, 2026.

Aditi Sarkar | 12 November 2026

Lucid Diagnostics Posts $32.3M Nine-Month Net Loss in Q3 2026

Lucid Diagnostics Inc. filed its Form 10-Q with the SEC on November 12, 2026, covering the quarterly period ended September 30, 2026, disclosing a net loss of $6.7 million for the third quarter and $32.3 million for the nine months ended September 30, 2026.

Aakashdeep | 12 November 2026

SeaStar Medical Posts $11.78M Net Loss Through Q3 2026

SeaStar Medical Holding Corporation filed its Form 10-Q for the quarterly period ended September 30, 2026 with the SEC on November 12, 2026, reporting financial results for the three and nine months ended on that date.

Anjali Anand | 12 November 2026

Theriva Biologics Q3 2026: $8.5M Cash, Net Loss Narrows

Theriva Biologics, Inc. filed its quarterly report on Form 10-Q with the SEC on November 12, 2026, covering the three and nine months ended September 30, 2026, disclosing a continued operating loss alongside a significant reduction in operating expenses compared to the prior-year period.

Aakashdeep | 12 November 2026

CorMedix Q3 2026: Net Loss of $14.7M as Product Sales Dip

CorMedix Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the Securities and Exchange Commission on November 12, 2026, reporting a net loss of $14.7 million for the third quarter and net income of $49.9 million for the nine-month …

Shwetambri Chauhan | 12 November 2026
Support

Hi! How can we help you today?

Loading…